Search

Your search keyword '"Conlin, Alison"' showing total 167 results
Start Over Author "Conlin, Alison"
167 results on '"Conlin, Alison"'

1. Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904)

Author

Michel, Alissa M., Yi, Haeseung, Amenta, Jacquelyn, Collins, Nicole, Vaynrub, Anna, Umakanth, Subiksha, Anderson, Garnet, Arnold, Katie, Law, Cynthia, Pruthi, Sandhya, Sandoval-Leon, Ana, Shirley, Rachel, Perdekamp, Maria Grosse, Colonna, Sarah, Krisher, Stacy, King, Tari, Yee, Lisa D., Ballinger, Tarah J., Braun-Inglis, Christa, Mangino, Debra A., Wisinski, Kari, DeYoung, Claudia A., Ross, Masey, Floyd, Justin, Kaster, Andrea, VanderWalde, Lindi, Saphner, Thomas J., Zarwan, Corrine, Lo, Shelly, Graham, Cathy, Conlin, Alison, Yost, Kathleen, Agnese, Doreen, Jernigan, Cheryl, Hershman, Dawn L., Neuhouser, Marian L., Arun, Banu, Crew, Katherine D., and Kukafka, Rita

Published
2024
Full Text
View/download PDF

2. A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

Author

Page, David B., Pucilowska, Joanna, Chun, Brie, Kim, Isaac, Sanchez, Katherine, Moxon, Nicole, Mellinger, Staci, Wu, Yaping, Koguchi, Yoshinobu, Conrad, Valerie, Redmond, William L., Martel, Maritza, Sun, Zhaoyu, Campbell, Mary B., Conlin, Alison, Acheson, Anupama, Basho, Reva, McAndrew, Philomena, El-Masry, Mary, Park, Dorothy, Bennetts, Laura, Seitz, Robert S., Nielsen, Tyler J., McGregor, Kimberly, Rajamanickam, Venkatesh, Bernard, Brady, Urba, Walter J., and McArthur, Heather L.

Published
2023
Full Text
View/download PDF

3. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

Author

Lin, Nancy U, Borges, Virginia, Anders, Carey, Murthy, Rashmi K, Paplomata, Elisavet, Hamilton, Erika, Hurvitz, Sara, Loi, Sherene, Okines, Alicia, Abramson, Vandana, Bedard, Philippe L, Oliveira, Mafalda, Mueller, Volkmar, Zelnak, Amelia, DiGiovanna, Michael P, Bachelot, Thomas, Chien, A Jo, O’Regan, Ruth, Wardley, Andrew, Conlin, Alison, Cameron, David, Carey, Lisa, Curigliano, Giuseppe, Gelmon, Karen, Loibl, Sibylle, Mayor, JoAl, McGoldrick, Suzanne, An, Xuebei, and Winer, Eric P

Subjects
Clinical Trials and Supportive Activities, Cancer, Clinical Research, Neurosciences, Breast Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Capecitabine, Disease Progression, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Pyridines, Quinazolines, Receptor, ErbB-2, Trastuzumab, Young Adult, Receptor, erbB-2, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeIn the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy and survival in participants with BMs.Patients and methodsPatients were randomly assigned 2:1 to tucatinib or placebo, in combination with trastuzumab and capecitabine. All patients underwent baseline brain magnetic resonance imaging; those with BMs were classified as active or stable. Efficacy analyses were performed by applying RECIST 1.1 criteria to CNS target lesions by investigator assessment. CNS-PFS (intracranial progression or death) and overall survival (OS) were evaluated in all patients with BMs. Confirmed intracranial objective response rate (ORR-IC) was evaluated in patients with measurable intracranial disease.ResultsThere were 291 patients with BMs: 198 (48%) in the tucatinib arm and 93 (46%) in the control arm. The risk of intracranial progression or death was reduced by 68% in the tucatinib arm (hazard ratio [HR], 0.32; 95% CI, 0.22 to 0.48; P < .0001). Median CNS-PFS was 9.9 months in the tucatinib arm versus 4.2 months in the control arm. Risk of death was reduced by 42% in the tucatinib arm (OS HR, 0.58; 95% CI, 0.40 to 0.85; P = .005). Median OS was 18.1 versus 12.0 months. ORR-IC was higher in the tucatinib arm (47.3%; 95% CI, 33.7% to 61.2%) versus the control arm (20.0%; 95% CI, 5.7% to 43.7%; P = .03).ConclusionIn patients with HER2-positive breast cancer with BMs, the addition of tucatinib to trastuzumab and capecitabine doubled ORR-IC, reduced risk of intracranial progression or death by two thirds, and reduced risk of death by nearly half. To our knowledge, this is the first regimen to demonstrate improved antitumor activity against BMs in patients with HER2-positive breast cancer in a randomized, controlled trial.

Published
2020

5. Comparing Mini-Cog and Blessed Orientation-Memory-Concentration test for evaluating cognition in older patients with advanced cancer

Author

Kyi, Kaitlin, primary, Consagra, William, additional, Culakova, Eva, additional, Berkhof, Lucia, additional, Janelsins, Michelle, additional, Conlin, Alison, additional, Bearden, James, additional, Berenberg, Jeffrey, additional, Canin, Beverly, additional, Mohile, Supriya, additional, and Magnuson, Allison, additional

Published
2024
Full Text
View/download PDF

7. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Author

Calfa, Carmen J., Rothe, Michael, Mangat, Pam K., Garrett-Mayer, Elizabeth, Ahn, Eugene R., Burness, Monika L., Gogineni, Keerthi, Rohatgi, Nitin, Al Baghdadi, Tareq, Conlin, Alison, Gaba, Anu, Hamid, Omid, Krishnamurthy, Jairam, Gavini, Naga Jyothi, Gold, Philip J., Rodon, Jordi, Rueter, Jens, Thota, Ramya, Grantham, Gina N., and Hinshaw, Dominique C.

Subjects
SUNITINIB, CANCER patients, BREAST cancer, METASTATIC breast cancer, DRUG target
Abstract

PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations known to be drug targets. Results from cohorts of patients with metastatic breast cancer (BC) with FGFR1 and FGFR2 alterations treated with sunitinib are reported. METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. Simon's two-stage design was used with a primary end point of disease control (DC), defined as objective response (OR) or stable disease of at least 16 weeks duration (SD16+) according to RECIST v1.1. Secondary end points included OR, progression-free survival, overall survival, duration of response, duration of stable disease, and safety. RESULTS: Forty patients with BC with FGFR1 (N = 30; amplification only n = 26, mutation only n = 1, both n = 3) or FGFR2 (N = 10; amplification only n = 2, mutation only n = 6, both n = 2) alterations were enrolled. Three patients in the FGFR1 cohort were not evaluable for efficacy; all patients in the FGFR2 cohort were evaluable. For the FGFR1 cohort, two patients with partial response and four with SD16+ were observed for DC and OR rates of 27% (90% CI, 13 to 100) and 7% (95% CI, 1 to 24), respectively. The null hypothesis of 15% DC rate was not rejected (P =.169). No patients achieved DC in the FGFR2 cohort (P = 1.00). Thirteen of the 40 total patients across both cohorts had at least one grade 3-4 adverse event or serious adverse event at least possibly related to sunitinib. CONCLUSION: Sunitinib did not meet prespecified criteria to declare a signal of antitumor activity in patients with BC with either FGFR1 or FGFR2 alterations. Other treatments and clinical trials should be considered for these patient populations. Sunitinib did not demonstrate antitumor activity in patients with FGFR1-/2-amplified or -mutated breast cancer. @ASCO #TAPUR [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. TIPS-19 TRIAL IN PROGRESS: SECONDARY BRAIN METASTASES PREVENTION AFTER ISOLATED INTRACRANIAL PROGRESSION ON TRASTUZUMAB/PERTUZUMAB OR T-DM1 IN PATIENTS WITH ADVANCED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2+ BREAST CANCER WITH THE ADDITION OF TUCATINIB (BRIDGET)

Author

Van Swearingen, Amanda, primary, Sammons, Sarah, additional, Noteware, Laura, additional, Bagegni, Nusayba, additional, Moulton, Kelly, additional, Threatt, Stevie, additional, Jaggers, Denise, additional, Shea, Shannon, additional, Lipp, Eric, additional, Riley, Erin, additional, Jung, Sin-Ho, additional, Broadwater, Gloria, additional, Ross, Masey, additional, Strickland, Kimberly, additional, Beyer, Sasha, additional, Conlin, Alison, additional, Morikawa, Aki, additional, Murthy, Rashmi, additional, and Anders, Carey, additional

Published
2023
Full Text
View/download PDF

9. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5

Author

Smith, John W., II, Buyse, Marc E., Rastogi, Priya, Geyer, Charles E., Jr., Jacobs, Samuel A., Patocskai, Erica J., Robidoux, André, Conlin, Alison K., Ansari, Bilal, Keogh, George P., Stella, Philip J., Gross, Howard M., Lord, Raymond S., Polikoff, Jonathan A., Mauquoi, Celine, Mamounas, Eleftherios P., Swain, Sandra M., and Wolmark, Norman

Published
2017
Full Text
View/download PDF

11. Abstract OT1-15-01: SWOG 1904: Cluster-randomized controlled trial of patient and provider decision support to increase chemoprevention informed choice among women with atypical hyperplasia or lobular carcinoma in situ (MiCHOICE)

Author

Crew, Katherine D., primary, Anderson, Garnet, additional, Arnold, Kathryn, additional, Stieb, Andrew, additional, Amenta, Jacquelyn N., additional, Law, Cynthia, additional, Sandoval-Leon, Ana, additional, Colonna, Sarah, additional, King, Tari, additional, Mangino, Debra, additional, Pruthi, Sandhya, additional, Perdekamp, Maria Grosse, additional, Braun-Inglis, Christa, additional, Krisher, Stacy, additional, Yee, Lisa, additional, Bertoni, Danielle, additional, Seaward, Samantha, additional, Wisinski, Kari B., additional, Floyd, Justin, additional, Zarwan, Corrine, additional, Ballinger, Tarah J., additional, VanderWalde, Lindi, additional, Ross, Masey M., additional, Steen, Preston, additional, Lo, Shelly, additional, Conlin, Alison, additional, Yost, Kathleen, additional, Ellerton, John, additional, Lin, Erin, additional, Pederson, Holly J., additional, Sardesai, Sagar, additional, Jernigan, Cheryl, additional, Hershman, Dawn, additional, Neuhouser, Marian L., additional, Arun, Banu K., additional, and Kukafka, Rita, additional

Published
2023
Full Text
View/download PDF

12. A phase Ib trial evaluating the safety, efficacy, and immunologic effects of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer

Author

Page, David, primary, Pucilowska, Joanna, additional, Chun, Brie, additional, Kim, Isaac, additional, Sanchez, Katherine, additional, Moxon, Nicole, additional, Mellinger, Staci, additional, Wu, Yaping, additional, Koguchi, Yoshinobu, additional, Conrad, Valerie, additional, Redmond, William, additional, Sun, Zhaoyu, additional, Martel, Maritza, additional, Campbell, Mary, additional, Conlin, Alison, additional, Acheson, Anupama, additional, Basho, Reva, additional, McAndrew, Philomena, additional, El-Masry, Mary, additional, Park, Dorothy, additional, Bennetts, Laura, additional, Seitz, Robert, additional, Nielsen, Tyler, additional, McGregor, Kimberly, additional, Rajamanickam, Venkatesh, additional, Bernard, Brady, additional, Urba, Walter, additional, and McArthur, Heather, additional

Published
2022
Full Text
View/download PDF

13. Association of 27-gene IO score with outcome in a phase Ib trial of pembrolizumab (pembro) plus chemotherapy (CT) in metastatic triple-negative breast cancer (mTNBC).

Author

Page, David B., primary, Collins, Krystle Louise, additional, Rajamanickam, Venkatesh, additional, Moxon, Nicole, additional, Mellinger, Staci L., additional, Conlin, Alison Katherine, additional, Seitz, Robert, additional, McGregor, Kim, additional, Nielsen, Tyler J., additional, and McArthur, Heather L., additional

Published
2022
Full Text
View/download PDF

15. A randomized trial of fulvestrant, everolimus and anastrozole in the front-line treatment of advanced hormone receptor-positive breast cancer, SWOG S1222

Author

Moore, Halle CF, Barlow, William E., Somlo, George, Gralow, Julie R., Schott, Anne F., Hayes, Daniel F., Kuhn, Peter, Hicks, James B., Welter, Lisa, Dy, Philip A., Yeon, Christina H., Conlin, Alison K., Balcueva, Ernie, Lew, Danika L., Tripathy, Debasish, Pusztai, Lajos, and Hortobagyi, Gabriel N.

Subjects
Receptors, Estrogen, Receptor, ErbB-2, Antineoplastic Combined Chemotherapy Protocols, Humans, Breast Neoplasms, Female, Everolimus, Anastrozole, Fulvestrant, Article
Abstract

PURPOSE: Metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer is an important cause of cancer mortality. Endocrine treatment with or without additional targeted therapies has been the mainstay of treatment. This trial was designed to evaluate the combination of fulvestrant plus everolimus versus fulvestrant, everolimus and anastrozole compared to fulvestrant alone in the first-line treatment of advanced HR-positive, HER2-negative breast cancer. EXPERIMENTAL DESIGN: This randomized placebo-controlled trial included postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had received no prior systemic therapy for metastatic disease. Participants were randomized to one of three treatment arms and the primary outcome was progression-free survival (PFS), comparing combinations of fulvestrant and everolimus with or without anastrozole to fulvestrant alone. Circulating tumor cells (CTC), as measured with two different methods, and circulating tumor DNA (ctDNA) were evaluated serially prior to treatment and the beginning of the second cycle of therapy. RESULTS: Due in part to changes in clinical practice, the study was closed after accruing only 37 participants. There was no evidence that everolimus-containing combination treatment improved PFS or overall survival relative to fulvestrant alone. When modeled continuously, an association was observed of baseline CTC and ctDNA with poorer survival. CONCLUSION: Although power of the study was limited, the findings were unable to support the routine use of everolimus combination endocrine therapy in the first-line treatment of advanced hormone-sensitive breast cancer. Prognostic impact of baseline ctDNA and copy number variations in CTC was demonstrated.

Published
2022

17. Abstract OT1-18-03: The neoIRX trial:locoregional cytokine therapy to promote immunologic priming and enhanced response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)

Author

Sanchez, Katherine, primary, Conlin, Alison, additional, Peddi, Parvin, additional, Stanton, Sasha, additional, Ruzich, Janet, additional, Perlewitz, Kelly, additional, Wu, Yaping, additional, Moxon, Nicole, additional, Mellinger, Staci, additional, Sun, Zhaoyu, additional, Redmond, William, additional, and Page, David B, additional

Published
2022
Full Text
View/download PDF

18. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

Author

Tolaney, Sara M., primary, Beeram, Muralidhar, additional, Beck, J. Thaddeus, additional, Conlin, Alison, additional, Dees, E. Claire, additional, Puhalla, Shannon L., additional, Rexer, Brent N., additional, Burris, Howard A., additional, Jhaveri, Komal, additional, Helsten, Teresa, additional, Becerra, Carlos, additional, Kalinsky, Kevin, additional, Moore, Kathleen N., additional, Manuel, Allison M., additional, Lithio, Andrew, additional, Price, Gregory L., additional, Chapman, Sonya C., additional, Litchfield, Lacey M., additional, and Goetz, Matthew P., additional

Published
2022
Full Text
View/download PDF

19. Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer

Author

Chun, Brie, primary, Pucilowska, Joanna, additional, Chang, ShuChing, additional, Kim, Isaac, additional, Nikitin, Benjamin, additional, Koguchi, Yoshinobu, additional, Redmond, William L, additional, Bernard, Brady, additional, Rajamanickam, Venkatesh, additional, Polaske, Nathan, additional, Fields, Paul A, additional, Conrad, Valerie, additional, Schmidt, Mark, additional, Urba, Walter J, additional, Conlin, Alison K, additional, McArthur, Heather L, additional, and Page, David B, additional

Published
2022
Full Text
View/download PDF

20. Manual scalp cooling in early-stage breast cancer case report: Value of caretaker training and patient experience to optimize efficacy and patient selection

Author

Rezayee, Manaz, primary, Moxon, Nicole, additional, Mellinger, Staci, additional, Seino, Amanda Y., additional, Fredrich, Nicole E., additional, Kelly, Tracy L., additional, Mulligan, Susan, additional, Uche, Ijeoma, additional, Urba, Walter J., additional, Conlin, Alison K., additional, Ruzich, Janet, additional, and Page, David B., additional

Published
2021
Full Text
View/download PDF

21. A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222

Author

Moore, Halle C.F., primary, Barlow, William E., additional, Somlo, George, additional, Gralow, Julie R., additional, Schott, Anne F., additional, Hayes, Daniel F., additional, Kuhn, Peter, additional, Hicks, James B., additional, Welter, Lisa, additional, Dy, Philip A., additional, Yeon, Christina H., additional, Conlin, Alison K., additional, Balcueva, Ernie, additional, Lew, Danika L., additional, Tripathy, Debasish, additional, Pusztai, Lajos, additional, and Hortobagyi, Gabriel N., additional

Published
2021
Full Text
View/download PDF

22. 94 Effects of chemoimmunotherapy on the peripheral blood: insights from immune monitoring of a phase Ib trial of pembrolizumab and paclitaxel or capecitabine for triple-negative breast cancer (TNBC)

Author

Chun, Brie, primary, Pucilowska, Joanna, additional, Chang, Shu Ching, additional, Kim, Isaac, additional, Nikitin, Benjamin, additional, Koguchi, Yoshinobu, additional, Redmond, William, additional, Bernard, Brady, additional, Rajamanickam, Venkatesh, additional, Polaske, Nathan, additional, Fields, Paul, additional, Conrad, Valerie, additional, Schmidt, Mark, additional, Urba, Walter, additional, Conlin, Alison, additional, McArthur, Heather, additional, and Page, David, additional

Published
2021
Full Text
View/download PDF

23. 398 neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)

Author

Sanchez, Katherine, primary, Conlin, Alison, additional, Peddi, Parvin, additional, Stanton, Sasha, additional, Ruzich, Janet, additional, Perlewitz, Kelly, additional, Wu, Yaping, additional, Moxon, Nicole, additional, Mellinger, Staci, additional, Sun, Zhaoyu, additional, Redmond, William, additional, and Page, David, additional

Published
2021
Full Text
View/download PDF

26. Physical Activity Patterns and Relationships With Cognitive Function in Patients With Breast Cancer Before, During, and After Chemotherapy in a Prospective, Nationwide Study

Author

Salerno, Elizabeth A., primary, Culakova, Eva, additional, Kleckner, Amber S., additional, Heckler, Charles E., additional, Lin, Po-Ju, additional, Matthews, Charles E., additional, Conlin, Alison, additional, Weiselberg, Lora, additional, Mitchell, Jerry, additional, Mustian, Karen M., additional, and Janelsins, Michelle C., additional

Published
2021
Full Text
View/download PDF

28. Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) withFGFR1mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Author

Calfa, Carmen, primary, Rothe, Michael, additional, Mangat, Pam K., additional, Garrett-Mayer, Elizabeth, additional, Ahn, Eugene, additional, Gogineni, Keerthi, additional, Rohatgi, Nitin, additional, Burness, Monika L., additional, Gaba, Anu, additional, Hamid, Omid, additional, Albaghdadi, Tareq, additional, Conlin, Alison, additional, Gold, Philip, additional, Rodon, Jordi, additional, Thota, Ramya, additional, and Schilsky, Richard L., additional

Published
2021
Full Text
View/download PDF

29. Effects of yoga, cognitive behavioral therapy, and a behavioral placebo on sleep: A nationwide multicenter phase III RCT in cancer survivors.

Author

Lin, Po-Ju, primary, Heckler, Charles E., additional, Culakova, Eva, additional, Xu, Huiwen, additional, Dunne, Richard Francis, additional, Gilmore, Nikesha, additional, Hardy, Sara, additional, Kleckner, Amber, additional, Kleckner, Ian, additional, Loh, Kah Poh, additional, Janelsins, Michelle Christine, additional, Peppone, Luke Joseph, additional, Vander Woude, Amy C., additional, Conlin, Alison Katherine, additional, Jaslowski, Anthony John, additional, and Mustian, Karen Michelle, additional

Published
2021
Full Text
View/download PDF

30. Additional file 1 of The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy

Author

Gilmore, Nikesha, Supriya Mohile, Lianlian Lei, Culakova, Eva, Mohamed, Mostafa, Magnuson, Allison, Kah Poh Loh, Maggiore, Ronald, Belcher, Elizabeth, Conlin, Alison, Weiselberg, Lora, Ontko, Mary, and Janelsins, Michelle

Abstract

Additional file 1: Table S1. Association of Pre-Chemotherapy Cell Counts with Pre-Chemotherapy Frailty also controlling for the number of days between pre-chemotherapy lab draw and start of chemotherapy. Table S2. Association of Change in Cell Counts (Pre to Post-Chemotherapy) with Post-Chemotherapy Frailty also controlling for the number of days between post-chemotherapy lab draw and end of chemotherapy. Table S3. Association of Change in Cell Counts (Pre to Post-Chemotherapy) with Post-Chemotherapy Frailty in patients who received growth factor with chemotherapy. Table S4. Association of Pre-Chemotherapy Cell Counts with Frailty at Post-Chemotherapy and 6 Month Post-Chemotherapy Time-Points in Patients with Breast Cancer. Table S5. Association of Pre-Chemotherapy Cell Counts with Frailty at Post-Chemotherapy and 6 Month Post-Chemotherapy Time-Points in Patients with Breast Cancer in patients who received growth factor with chemotherapy. Table S6. Association of Change in Cell Counts (Pre to Post-Chemotherapy) with 6-Month Post-Chemotherapy Frailty.

Published
2021
Full Text
View/download PDF

34. Caregiver–Oncologist Prognostic Concordance, Caregiver Mastery, and Caregiver Psychological Health and Quality of Life

Author

Loh, Kah Poh, primary, Mohamed, Mostafa R., additional, Kadambi, Sindhuja, additional, Culakova, Eva, additional, Xu, Huiwen, additional, Magnuson, Allison, additional, Flannery, Marie, additional, Duberstein, Paul R., additional, Epstein, Ronald M., additional, McHugh, Colin, additional, Nipp, Ryan D., additional, Trevino, Kelly M., additional, Sanapala, Chandrika, additional, Hall, Bianca A., additional, Canin, Beverly, additional, Gayle, Arlene A., additional, Conlin, Alison, additional, Bearden, James, additional, and Mohile, Supriya G., additional

Published
2021
Full Text
View/download PDF

37. The Longitudinal Relationship between Immune Cell Profiles and Frailty in Patients with Breast Cancer receiving Chemotherapy

Author

Gilmore, Nikesha, primary, Mohile, Supriya, additional, Lei, Lianlian, additional, Culakova, Eva, additional, Mohamed, Mostafa, additional, Magnuson, Allison, additional, Loh, Kah Poh, additional, Maggiore, Ronald, additional, Belcher, Elizabeth, additional, Conlin, Alison, additional, Weiselberg, Lora, additional, Ontko, Mary, additional, and Janelsins, Michelle, additional

Published
2020
Full Text
View/download PDF

38. Caregiver-oncologist concordance in patient prognosis, caregiver depression, and caregiver mastery.

Author

Loh, Kah Poh, primary, Culakova, Eva, additional, Xu, Huiwen, additional, Kadambi, Sindhuja M, additional, Magnuson, Allison, additional, Flannery, Marie Anne, additional, Duberstein, Paul, additional, Epstein, Ronald M., additional, McHugh, Colin, additional, Nipp, Ryan David, additional, Trevino, Kelly Marie, additional, Sanapala, Chandrika, additional, Canin, Beverly, additional, Gayle, Arlene Angela, additional, Conlin, Alison Katherine, additional, Bearden, James, additional, and Mohile, Supriya Gupta, additional

Published
2020
Full Text
View/download PDF

39. Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).

Author

Okines, Alicia Frances Clare, primary, Paplomata, Elisavet, additional, Wahl, Tanya A., additional, Wright, Gail Lynn Shaw, additional, Sutherland, Stephanie, additional, Jakobsen, Erik, additional, Valdes, Frances, additional, Chan, Arlene, additional, Clark, Amy Sanders, additional, Conlin, Alison Katherine, additional, Lustberg, Maryam B., additional, Specht, Jennifer M., additional, Pluard, Timothy J., additional, Zhu, Xiaofu, additional, Krop, Ian E., additional, Gelmon, Karen A., additional, Slamon, Dennis J., additional, Ramos, Jorge, additional, An, Grace, additional, and Hamilton, Erika Paige, additional

Published
2020
Full Text
View/download PDF

40. Effects of YOCAS yoga, cognitive behavioral therapy, and survivorship health education on insomnia: A URCC NCORP Research Base Phase III RCT in 740 cancer survivors.

Author

Mustian, Karen Michelle, primary, Lin, Po-Ju, additional, Culakova, Eva, additional, Bautista, Javier, additional, Xu, Huiwen, additional, Mohile, Supriya Gupta, additional, Janelsins, Michelle Christine, additional, Peppone, Luke Joseph, additional, Kleckner, Amber, additional, Kleckner, Ian, additional, Loh, Kah Poh, additional, Dunne, Richard Francis, additional, Gilmore, Nikesha, additional, Conlin, Alison Katherine, additional, Gococo, Kim Ong, additional, and Jaslowski, Anthony John, additional

Published
2020
Full Text
View/download PDF

41. Inflammatory and clinical risk factors for chemotherapy-induced peripheral neuropathy (CIPN): A nationwide longitudinal study in 143 cancer patients during chemotherapy.

Author

Kleckner, Ian, primary, Jusko, Todd, additional, Culakova, Eva, additional, Kleckner, Amber, additional, Asare, Matthew, additional, Inglis, Julia Ellen, additional, Loh, Kah Poh, additional, Peppone, Luke Joseph, additional, Berenberg, Jeffrey L., additional, Conlin, Alison Katherine, additional, Ossip, Deborah J., additional, and Mustian, Karen Michelle, additional

Published
2020
Full Text
View/download PDF

42. A Phase Ib Study of Preoperative, Locoregional IRX-2 Cytokine Immunotherapy to Prime Immune Responses in Patients with Early-Stage Breast Cancer

Author

Page, David B., primary, Pucilowska, Joanna, additional, Sanchez, Katherine G., additional, Conrad, Valerie K., additional, Conlin, Alison K., additional, Acheson, Anupama K., additional, Perlewitz, Kelly S., additional, Imatani, James H., additional, Aliabadi-Wahle, Shaghayegh, additional, Moxon, Nicole, additional, Mellinger, Staci L., additional, Seino, Amanda Y., additional, Martel, Martiza, additional, Wu, Yaping, additional, Sun, Zhaoyu, additional, Redmond, William L., additional, Rajamanickam, Venkatesh, additional, Waddell, Dottie, additional, Laxague, Deborah, additional, Shah, Monil, additional, Chang, Shu-Ching, additional, and Urba, Walter J., additional

Published
2020
Full Text
View/download PDF

43. Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis

Author

Mano, Max S, primary, Loibl, Sibylle, additional, Mamounas, Eleftherios P., additional, von Minckwitz, Gunter, additional, Huang, Chiun-Sheng, additional, Untch, Michael, additional, Wolmark, Norman, additional, Wapnir, Irene L., additional, Yang, Youngsen, additional, Conlin, Alison K., additional, Kümmel, Sherko, additional, Saghatchian, Mahasti, additional, DiGiovanna, Michael P., additional, Strunk, Claudia, additional, Zimovjanova, Martina, additional, Song, Chunyan, additional, Liu, Haying, additional, Tesarowski, David, additional, Blotner, Steven, additional, Lam, Lisa H., additional, Smitt, Melanie, additional, and Geyer, Charles E., additional

Published
2020
Full Text
View/download PDF

44. Abstract P2-12-14: A pilot evaluation of cold-capping efficacy under real world conditions for the prevention of chemotherapy-induced alopecia in early stage breast cancer

Author

Rezayee, Manaz, primary, Conlin, Alison K, additional, Ruzich, Janet, additional, Fredrich, Nicole, additional, Seino, Amanda Y, additional, Mulligan, Susan, additional, Kelly, Tracy L, additional, Cramer, Julie, additional, Urba, Walter J, additional, and Page, David B, additional

Published
2020
Full Text
View/download PDF

45. Associations of uncertainty with psychological status and quality of life (QoL) among 527 older patients with advanced cancer.

Author

Babu, Dilip Sankar, primary, Loh, Kah Poh, additional, Bautista, Javier, additional, Xu, Huiwen, additional, Culakova, Eva, additional, Canin, Beverly E., additional, Conlin, Alison Katherine, additional, Bearden, James, additional, Berenberg, Jeffrey L., additional, Zhang, Yingzi, additional, Wells, Megan, additional, Epstein, Ronald M., additional, Dale, William, additional, Duberstein, Paul, additional, Mohile, Supriya Gupta, additional, and Tejani, Mohamedtaki Abdulaziz, additional

Published
2019
Full Text
View/download PDF

46. Evaluation of immunotherapy (I-O)-associated immune cell (IC) dynamics and PD-L1 expression using multispectral immunohistochemistry (mIHC) and single-cell hierarchical regression modeling in early-stage breast cancer (ESBC).

Author

Sanchez, Katherine, primary, Martel, Maritza, additional, Chang, Shu-Ching, additional, Wu, Yaping, additional, Sun, Zhaoyu, additional, Nyberg, Richard, additional, Redmond, William L, additional, Pucilowska, Joanna, additional, Aliabadi-Wahle, Shaghayegh, additional, Imatani, James, additional, Conlin, Alison Katherine, additional, Bernard, Brady, additional, Shah, Monil, additional, Wadell, Dottie, additional, Laxague, Deborah R., additional, Wen, Lu, additional, Li, Qiao, additional, Wolf, Gregory T., additional, Urba, Walter John, additional, and Page, David B., additional

Published
2019
Full Text
View/download PDF

47. Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).

Author

Page, David B., primary, Chun, Brie, additional, Pucilowska, Joanna, additional, Kim, Isaac, additional, Sanchez, Katherine, additional, Redmond, William L, additional, Sun, Zhaoyu, additional, Wu, Yaping, additional, Feryn, Alicia, additional, Martel, Maritza, additional, Abaya, Christina DiLauro, additional, Wadell, Dottie, additional, Mellinger, Staci L., additional, Moxon, Nicole, additional, Urba, Walter John, additional, McAndrew, Philomena, additional, El-Masry, Maryliza, additional, Basho, Reva K., additional, Conlin, Alison Katherine, additional, and McArthur, Heather L., additional

Published
2019
Full Text
View/download PDF

48. Effects of a Home‐based Exercise Program on Anxiety and Mood Disturbances in Older Adults with Cancer Receiving Chemotherapy

Author

Loh, Kah Poh, primary, Kleckner, Ian R., additional, Lin, Po‐Ju, additional, Mohile, Supriya G., additional, Canin, Beverly E., additional, Flannery, Marie A., additional, Fung, Chunkit, additional, Dunne, Richard F., additional, Bautista, Javier, additional, Culakova, Eva, additional, Kleckner, Amber S., additional, Peppone, Luke J., additional, Janelsins, Michelle, additional, McHugh, Colin, additional, Conlin, Alison, additional, Cho, Jonathan K., additional, Kasbari, Sameer, additional, Esparaz, Benjamin T., additional, Kuebler, J. Philip, additional, and Mustian, Karen M., additional

Published
2019
Full Text
View/download PDF

49. Beliefs About Advanced Cancer Curability in Older Patients, Their Caregivers, and Oncologists

Author

Loh, Kah Poh, primary, Mohile, Supriya G., additional, Lund, Jennifer L., additional, Epstein, Ronald, additional, Lei, Lianlian, additional, Culakova, Eva, additional, McHugh, Colin, additional, Wells, Megan, additional, Gilmore, Nikesha, additional, Mohamed, Mostafa R., additional, Kamen, Charles, additional, Aarne, Valerie, additional, Conlin, Alison, additional, Bearden, James, additional, Onitilo, Adedayo, additional, Wittink, Marsha, additional, Dale, William, additional, Hurria, Arti, additional, and Duberstein, Paul, additional

Published
2019
Full Text
View/download PDF

50. Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial

Author

Kleckner, Ian R., primary, Kamen, Charles, additional, Cole, Calvin, additional, Fung, Chunkit, additional, Heckler, Charles E., additional, Guido, Joseph J., additional, Culakova, Eva, additional, Onitilo, Adedayo A., additional, Conlin, Alison, additional, Kuebler, J. Philip, additional, Mohile, Supriya, additional, Janelsins, Michelle, additional, and Mustian, Karen M., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results